GlobeNewswire Inc.··NaTScan Advances Allogeneic Cell Therapy Pipeline With FDA IND Clearances and Trial Enrollment Milestones
TScan completes Phase 1 trial enrollment and receives FDA clearance for two allogeneic cell therapy candidates, advancing its pipeline toward pivotal studies in 2026.
TCRXclinical trialTCR-T therapy